Introduction {#Sec1}
============

The acute respiratory distress syndrome (ARDS) is characterized by lung injury caused by either indirect or direct insults, which could be worsened by the way mechanical ventilation is applied \[[@CR1]\]. Indeed, tidal overdistension (volutrauma) and cyclic alveolar recruitment and derecruitment (atelectrauma) during ventilation may further damage the lungs, and increase local production and release of inflammatory mediators (biotrauma), eventually resulting in multiple organ dysfunction and death \[[@CR2]\]. So-called lung-protective ventilation strategies using low tidal volumes (6 mL/kg predicted body weight, PBW) and higher levels of positive end-expiratory pressure (PEEP) to prevent volutrauma, atelectrauma and biotrauma are by now widely accepted approaches in ARDS patients \[[@CR3]--[@CR7]\].

Extracorporeal membrane oxygenation (ECMO) is increasingly being used as a rescue therapy for refractory hypoxemia in ARDS patients \[[@CR8]\]. Initiation of ECMO allows reductions in the tidal volume size, PEEP and plateau pressure (Pplat) levels, as well as inspired oxygen fractions (FiO~2~) \[[@CR8]--[@CR10]\], which all may help to improve outcome via prevention of additional lung injury \[[@CR11], [@CR12]\]. The impact of different ventilator settings in ARDS patients undergoing ECMO is, however, unclear. Actually, to date, there have been no studies that have addressed the relationship between ventilator settings during ECMO and outcome of ARDS patients \[[@CR9]--[@CR16]\].

To examine the hypothesis that certain ventilator settings during ECMO are associated with outcome, we performed an individual patient data meta-analysis of observational studies in ventilated ARDS patients receiving ECMO for refractory hypoxemia, and determined which ventilator settings have an independent association with in-hospital mortality.

Methods {#Sec2}
=======

Setting and patients {#Sec3}
--------------------

We identified eligible studies by a blind electronic search by two authors of MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controlled Trials (CENTRAL) up to January 2016. All investigations describing ventilation practice in adult ARDS patients undergoing ECMO for refractory hypoxemia were considered for inclusion. All reviewed articles and cross-referenced studies from these articles were screened for pertinent information, and were assessed for evidence of quality using the Newcastle Ottawa Scale for observational studies.

Data collection {#Sec4}
---------------

After exclusion of duplicate patients from the retrieved databases, the following variables were assessed for each patient: (1) demographic data, (2) interval between initiation of ventilation and start of ECMO, (3) ECMO settings and complications, (4) ventilation settings and blood gas analysis parameters before and daily after initiation of ECMO, (5) laboratory and vital signs, and (6) in-hospital mortality. All settings, parameters and signs were collected once daily at a fixed moment in the morning as per protocols of the original studies.

Definitions {#Sec5}
-----------

Driving pressure (ΔP) was calculated as inspiratory Pplat minus the PEEP level (as measured in the ventilator). PaO~2~/FiO~2~ was calculated using the patient's PaO~2~ and the FiO~2~ set at the ventilator.

Outcome {#Sec6}
-------

The primary outcome was in-hospital mortality.

Analysis plan {#Sec7}
-------------

As a first step, ventilator settings and other parameters before and after initiation of ECMO were described and compared. The time between the start of mechanical ventilation and ECMO was categorized according to tertiles. Then, the associations between ventilator settings during ECMO and outcome were analyzed.

Statistical analysis {#Sec8}
--------------------

Normally distributed data were described as mean ± standard deviation while non-normally distributed data were described as median \[quartile range (QR = 25--75 %)\]. Categorical variables were described as proportions (%) \[[@CR17]\]. Continuous variables were compared using Student's *t* tests or analysis of variance *or* Mann--Whitney tests or Kruskal--Wallis tests according to the distribution of the variables. Categorical variables were compared using Chi-squared or Fisher's exact tests. Line graphs were used to show ventilatory settings and parameters during the first 3 days of ECMO.

Multiple imputation was conducted to deal with missing values in the retrieved database. For this imputation, the following variables were included: age, gender, BMI, risk of death, Sequential Organ Failure Assessment score (SOFA), chronic obstructive pulmonary disease (COPD), diabetes mellitus, Influenza H~1~N~1~ infection, time between start of mechanical ventilation and ECMO, tidal volume (in ml/kg PBW), PEEP, Pplat, peak pressure (Ppeak), and ΔP levels, respiratory rate, FiO~2~ (as set on the ventilator), minute ventilation, static compliance, PaCO~2~, pH, PaO~2~/FiO~2~, duration of mechanical ventilation and ECMO, ICU and hospital length of stay, mortality, and time until mortality. Multiple imputation was conducted using the method of predictive mean matching and ten databases were created. All the models were constructed using the databases after multiple imputation.

A multivariable model was built to quantify the association between predefined ventilation parameters and mortality, while controlling for other known risk factors. We conducted multi-level analyses to adjust for clustering of the data. Therefore, a frailty model was used to determine predictors of mortality by modeling it as the dependent variable. Independent variables were selected according to biologic plausibility, and when the univariate analysis *p* value was \<0.2. Then, a multivariable time-dependent frailty model \[presented as hazard ratio and 95 % CI (HR and 95 % CI)\] considering ΔP, FiO~2~, PaO~2~/FiO~2~, lactate and norepinephrine as time-dependent variables was built, with study treated as random effect. Only values from the first 3 days of ECMO were considered in this model. The cluster effects induced by the structure of the data were taken into account through random effects. In the multivariable model, statistical significance was set at *p* \< 0.05.

Since static compliance, Pplat level and Δ*P* showed high collinearity (Appendix Table 1, Appendix Fig. 1 in the Online Supplement), we chose to include only ΔP in the model. ΔP was chosen since recent studies and one individual patient data meta-analysis have suggested that the ΔP is the ventilatory parameter that best stratifies risk of death in ARDS patients receiving mechanical ventilation \[[@CR7], [@CR9], [@CR18], [@CR19]\]. As arterial pH and lactate levels also showed a high collinearity, we chose to include only lactate levels in the principal final model because lactate is more clinical relevant and associated with shock reversal \[[@CR20], [@CR21]\].

We conducted one post hoc analysis replacing ΔP by Pplat level to assess the additional impact of the later ventilatory parameter. In addition, we conducted another post hoc model including PEEP, Pplat and ΔP levels. We compared these three models (i.e., the model with the ΔP vs. the model with the Pplat levels) and assessed the fit of each model. To assess the possible relationship between the ventilatory parameters of interest (PEEP, Pplat and ΔP levels) and mortality, we conducted several mediation analyses (details of the mediation analysis are described in the Online Supplement).

All analyses were conducted with SPSS v.20 (IBM SPSS Statistics for Windows, v.20.0; IBM, Armonk, NY, USA) and R v.2.12.0 (R Foundation for Statistical Computing, Vienna, Austria). For all analyses, two-sided *p* \< 0.05 was considered significant.

Results {#Sec9}
=======

Cohort analyzed {#Sec10}
---------------

Sixty-one observational studies were evaluated for extraction of individual patient data. Fifty-two were not included for the following reasons: unable to send the individual patient data due to rejection or other reasons (*n* = 16); unable to establish contact with the authors (*n* = 15); ECMO provided for other indications than ARDS (*n* = 8); same cohort previously described (*n* = 5); and others (*n* = 8) (Appendix Fig. 2, Appendix Table 2 in the Online Supplement). Data from the remaining nine investigations were included and a total of 545 patients were pooled \[[@CR9], [@CR22]--[@CR29]\]. The characteristics of the included studies are shown in Appendix Tables 3 and 4 in the Online Supplement.

Baseline characteristics {#Sec11}
------------------------

Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. Pneumonia and pulmonary ARDS were the main diagnoses. Non-survivors were older, had lower body weight and body mass index, a higher risk of dying and higher SOFA scores. Median time from start of ventilation until initiation of ECMO was 48 (24--120) h; the difference in the median time from start of ventilation until initiation of ECMO between survivors and non-survivors was not statistically significant \[48 (24--120) vs. 72 (24--144) h; *p* = 0.061) (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of the patients and ventilatory parameters before ECMOAll\
(*n* = 545)Survivors\
(*n* = 353)Non-survivors\
(*n* = 192)*p* value^a^Age, years41.4 ± 14.039.7 ± 13.944.8 ± 13.6\<0.001Gender, male331 (60.7)205 (58.1)126 (67.2)0.030BMI, kg/m^2^29.6 ± 8.530.5 ± 9.028.1 ± 7.50.004Actual weight, kg86.6 ± 26.088.5 ± 27.383.5 ± 23.40.036PBW, kg65.0 ± 9.764.6 ± 10.165.5 ± 8.70.331Risk of death,  %^b^40.4 ± 25.937.6 ± 24.646.0 ± 27.60.001SOFA10.7 ± 4.310.2 ± 4.011.6 ± 4.80.002LIS3.5 ± 0.53.5 ± 0.53.5 ± 0.50.753Co-morbidities COPD60 (11.0)36 (10.3)24 (12.5)0.835 Diabetes42 (7.7)25 (7.1)17 (8.8)0.644 Hypertension42 (7.7)24 (6.9)18 (9.4)0.407 CAD2 (0.4)1 (0.3)1 (0.5)0.926 HIV2 (0.4)0 (0.0)2 (1.0)0.252 H~1~N~1~264 (48.5)168 (48.0)96 (50.0)0.575 Time between MV-ECMO, h48.0 (24.0--120.0)48.0 (24.0--120.0)72.0 (24.0--144.0)0.061 ≤24 h228 (41.8)157 (44.5)71 (37.0) 24--72 h110 (20.2)78 (22.1)30 (15.6)0.006 \>72 h207 (38.0)118 (33.4)91 (47.4)Indication of ECMO Refractory hypoxemia526 (96.5)340 (97.1)186 (96.9)0.247 Hypercapnia19 (3.5)10 (2.9)9 (3.1)Severity of ARDS Mild3 (0.6)2 (0.3)1 (0.5)0.544 Moderate52 (9.6)37 (10.6)15 (7.9) Severe490 (89.9)314 (89.1)176 (91.6)Type of ARDS Pulmonary501 (92.4)325 (92.1)176 (91.7)0.812 Non-pulmonary44 (7.6)28 (7.9)16 (8.3)Cause of ARDS Pneumonia454 (83.8)295 (84.2)159 (82.8)0.790 Non-pulmonary sepsis13 (1.8)9 (1.7)4 (2.1) Trauma48 (8.9)32 (9.2)16 (8.3) Other30 (5.5)17 (4.9)13 (6.8)Mode of ventilation Pressure-controlled273 (50.1)188 (53.2)85 (44.2)0.116 Volume-controlled107 (19.6)57 (16.2)48 (24.9) SIMV59 (10.8)32 (9.3)27 (14.0) Pressure support1 (0.2)1 (0.5)0 (0.0) HFPV85 (15.6)61 (17.1)24 (12.4) APRV12 (2.2)4 (1.4)8 (4.2) Other8 (1.5)7 (2.3)1 (0.3)Ventilatory parameters Tidal volume, ml/kg PBW6.0 ± 1.96.2 ± 1.85.8 ± 2.10.032 Tidal volume, ml/kg ABW4.8 ± 1.84.8 ± 1.84.9 ± 1.80.840 PEEP, cmH~2~O13.7 ± 4.313.7 ± 4.013.6 ± 5.00.733 FiO~2~,  %0.90 ± 0.170.91 ± 0.170.91 ± 0.160.944 Plateau pressure, cmH~2~O31.1 ± 5.730.7 ± 5.232.2 ± 6.30.032 Driving pressure, cmH~2~O17.7 ± 6.816.9 ± 6.419.4 ± 7.30.004 Respiratory rate, bpm21.9 ± 7.921.2 ± 6.923.2 ± 9.40.012 Minute ventilation, l/min9.1 ± 3.99.0 ± 3.79.2 ± 4.20.644 Static compliance^c^26.8 ± 16.927.7 ± 17.624.8 ± 15.20.178Laboratory parameters PaO~2~, mmHg64.8 ± 21.264.4 ± 23.265.2 ± 20.20.715 PaO~2~/FiO~2~, mmHg72.6 ± 38.573.2 ± 38.671.3 ± 39.00.610 PaCO~2~, mmHg58.3 ± 22.757.3 ± 22.160.3 ± 23.80.206 pHa7.27 ± 0.157.29 ± 0.147.24 ± 0.160.008 Lactate, mg/dL33.5 ± 36.429.4 ± 23.642.1 ± 42.10.031Hemodynamics MAP, mmHg70.8 ± 15.571.5 ± 16.471.3 ± 14.90.979 Norepinephrine, µg/kg/min^d^0.40 ± 1.290.32 ± 0.890.54 ± 1.900.258Data shown as mean ± standard deviation, number (percentage) or median (interquartile range)*ECMO* extracorporeal membrane oxygenation, *BMI* body mass index, *PBW* predicted body weight, *SOFA* sequential organ failure assessment, *COPD* chronic obstructive pulmonary disease, *CAD* coronary artery disease, *HIV* human immunodeficiency virus, *H* ~*1*~ *N* ~*1*~ influenza A virus subtype H~1~N~1~, *LIS* lung injury score, *MV* mechanical ventilation, *ARDS* acute respiratory distress syndrome, *PEEP* positive end-expiratory pressure, *BPM* breaths per minute, *SIMV* synchronized intermittent mandatory ventilation, *HFPV* high-frequency percussive ventilation, *APRV* airway pressure release ventilation, *ABW* actual body weight, *MIN* minutes, *FiO* ~*2*~ inspired fraction of oxygen^a^ *p* for survivor vs. no-survivor^b^Predicted by APACHE II, APACHE III, SAPS II or SAPS III^c^Static compliance calculated as tidal volume/plateau pressure minus PEEP (ml/cmH~2~O)^d^Defined as total dose during whole day divided by weight and 1440 min

Ventilatory parameters before and after initiation of ECMO {#Sec12}
----------------------------------------------------------

Table [1](#Tab1){ref-type="table"} shows ventilatory parameters before ECMO; Appendix Fig. 3 in the Online Supplement shows the distribution of modes of ventilation. The number of patients under ECMO and on ventilation on each follow-up day is shown in Fig. [1](#Fig1){ref-type="fig"}. Initiation of ECMO was accompanied by significant decreases in tidal volume size, PEEP and Pplat levels, ΔP, respiratory rate and minute ventilation (all *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). Also, significant increases in PaO~2~/FiO~2~ and arterial pH, and decreases in PaCO~2~ levels were noted (all *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}).Fig. 1(*Upper panel*) Cumulative incidence curve of in-hospital mortality; (*lower panel*) number of patients under mechanical ventilation (*orange line*), or ECMO (*blue line*) Table 2Parameters in the first day of ECMO and complicationsAll\
(*n* = 545)Survivors\
(*n* = 353)Non-survivors\
(*n* = 192)*p* value^a^Ventilatory parameters Tidal volume, ml/kg PBW4.0 ± 1.74.0 ± 1.64.0 ± 1.90.934 Tidal volume, ml/kg ABW3.2 ± 1.63.1 ± 1.53.4 ± 1.80.075 PEEP, cmH~2~O12.9 ± 3.413.0 ± 3.312.5 ± 3.70.125 FiO~2~0.69 ± 0.240.67 ± 0.230.74 ± 0.230.005 Plateau pressure, cmH~2~O26.2 ± 4.626.0 ± 4.326.7 ± 5.10.205 Driving pressure, cmH~2~O13.7 ± 5.313.3 ± 4.814.5 ± 6.20.048 Respiratory rate, bpm17.8 ± 8.017.4 ± 7.718.7 ± 8.70.105 Minute ventilation, l/min5.0 ± 3.24.8 ± 2.95.3 ± 3.30.117 Static compliance^b^23.2 ± 18.822.7 ± 16.924.1 ± 22.30.564Laboratory parameters PaO~2~, mmHg95.9 ± 55.996.8 ± 51.694.6 ± 64.90.702 PaO~2~/FiO~2~, mmHg152.5 ± 96.8158.3 ± 96.8139.1 ± 95.90.051 PaCO~2~, mmHg40.3 ± 9.540.1 ± 9.240.4 ± 9.70.764 pHa7.39 ± 0.117.41 ± 0.087.36 ± 0.14\<0.001 Lactate, mg/dL34.8 ± 38.129.9 ± 34.846.7 ± 43.00.003ECMO parameters Flow, l/min4.3 ± 1.14.3 ± 1.14.4 ± 1.10.482 Sweep gas flow, l/min6.2 ± 2.36.1 ± 2.16.4 ± 2.60.459Hemodynamics MAP, mmHg  Day 0175.8 ± 10.776.0 ± 9.571.4 ± 13.80.420  Day 0278.3 ± 12.778.8 ± 12.479.7 ± 16.90.496  Day 0380.7 ± 8.381.4 ± 8.578.0 ± 9.50.750 Norepinephrine, µg/kg/min^c^  Day 010.12 ± 0.390.11 ± 0.290.15 ± 0.550.377  Day 020.07 ± 0.300.07 ± 0.180.10 ± 0.480.915  Day 030.06 ± 0.250.06 ± 0.200.07 ± 0.340.535Complications Bleeding events136 (24.9)69 (19.5)67 (34.9)0.019 Intracerebral hemorrhage15 (2.8)3 (0.8)12 (6.2)\<0.001Data shown as mean ± standard deviation or number (percentage)*ECMO* extracorporeal membrane oxygenation, *PBW* predicted body weight, *PEEP* positive end-expiratory pressure, *BPM* breaths per minute, *ABW* actual body weight, *MIN* minutes, *FiO* ~*2*~ inspired fraction of oxygen^a^ *p* for survivor vs. no-survivor^b^Static compliance calculated as tidal volume/plateau pressure minus PEEP (ml/cmH~2~O)^c^Defined as total dose during whole day divided by weight and 1440 min Fig. 2Tidal volume size (*V* ~T~), respiratory rate, inspired oxygen fractions (FiO~2~), positive end-expiratory pressure (PEEP) levels, plateau pressure (Pplat) levels, and driving pressure (ΔP) in survivors (*orange line*) and non-survivors (*blue line*) during extracorporeal membrane oxygenation for the acute respiratory distress syndrome. *Before* before extracorporeal membrane oxygenation; days*1*,*2* and*3*, the first, second and third day of ECMO; data are presented as medians and their interquartile ranges, and only for patients that were still receiving ECMO Fig. 3PaO~2~/FiO~2~, PaCO~2~ levels, pHa, and lactate levels in survivors (*orange line*) and non-survivors (*blue line*) during extracorporeal membrane oxygenation (ECMO) for the acute respiratory distress syndrome. *Before* before extracorporeal membrane oxygenation; days*1*,*2* and*3*, the first, second and third day of ECMO; data are presented as medians and their interquartile ranges, and only for patients that were still receiving ECMO

Outcomes {#Sec13}
--------

In-hospital mortality of the present cohort was 35.2 %. A cumulative incidence curve of in-hospital mortality is shown in Fig. [1](#Fig1){ref-type="fig"}. Incidence of bleeding events including intracerebral haemorrhage was higher in non-survivors (34.9 vs. 19.5 %; *p* = 0.019 and 6.2 vs. 0.8 %; *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). Duration of ECMO, mechanical ventilation, ICU and hospital length of stay in survivors were 10 (6--15) days, 25 (15--39) days, 30 (18--46) days, and 38 (26--64) days, respectively.

In the first day of ECMO, compared to survivors, the non-survivors received ventilation with higher ΔP (*p* = 0.048) and higher FiO~2~ set at the ventilator (*p* = 0.005), and had lower PaO~2~/FiO~2~ (*p* = 0.051), lower arterial pH (*p* \< 0.001) and higher lactate levels (*p* = 0.003) (Table [2](#Tab2){ref-type="table"}).

Association between ventilator settings and mortality {#Sec14}
-----------------------------------------------------

Univariable analysis of factors associated with in-hospital mortality is provided in Appendix Table 5 in the Online Supplement. After adjusting for confounders, independent predictors of in-hospital mortality included a higher age, male gender, a lower body mass index, and higher lactate levels (Table [3](#Tab3){ref-type="table"}). The only ventilatory parameter during ECMO that showed an independent association with in-hospital mortality was a higher ΔP (Table [3](#Tab3){ref-type="table"}).Table 3Multivariable time-dependent frailty model with in-hospital mortality as the primary outcomeHR (95 %CI), *p*Age, years1.01 (1.00--1.02), 0.006Gender, male1.63 (1.21--2.21), 0.001BMI, kg/m^2^0.95 (0.93--0.97), \<0.001Risk of death, %^a^1.01 (0.99--1.01), 0.063SOFA1.03 (0.98--1.07), 0.252Time between MV-ECMO ≤24 h1.00 (Reference) 24--72 h0.70 (0.45--1.09), 0.112 \>72 h0.78 (0.58--1.05), 0.103Indication of ECMO Hypoxemia0.96 (0.34--2.70), 0.935 Hypercapnia1 (Reference)Ventilatory parameters PEEP, cmH~2~O-- FiO~2~,  %0.96 (0.40--2.30), 0.924 Driving pressure, cmH~2~O1.06 (1.03--1.10), \<0.001 Respiratory rate, bpm--Laboratory parameters PaO~2~/FiO~2~, mmHg1.00 (0.99--1.00), 0.431 PaCO~2~, mmHg0.99 (0.99--1.01), 0.891 Lactate, mg/dL1.00 (1.00--1.01), 0.005Hemodynamics (pre-ECMO) Norepinephrine, µg/kg/min^b^1.07 (0.88--1.29), 0.518The cluster effects induced by the structure of the data were taken into account through random effects in all models*ECMO* extracorporeal membrane oxygenation, *BMI* body mass index, *SOFA* sequential organ failure assessment, *MV* mechanical ventilation, *PEEP* positive end-expiratory pressure, *BPM* breaths per minute, *OR* odds ratio, *HR* hazard ratio, *CI* confidence interval, *FiO* ~*2*~ inspired fraction of oxygen, *HR* hazard ration^a^Predicted by APACHE II, APACHE III, SAPS II or SAPS III^b^Defined as total dose during whole day divided by weight and 1440 min

Post hoc analyses {#Sec15}
-----------------

Replacing ΔP by Pplat levels, higher age, male gender, lower BMI, higher lactate, lower PEEP and higher Pplat levels independently associated with in-hospital mortality (Appendix Table 6 in the Online Supplement). Including Pplat, PEEP and ΔP in the model, no parameter remained associated with in-hospital mortality. The comparison of the models is shown in Appendix Table 7 in the Online Supplement. Since the higher FiO~2~ observed in non-survivors from ECMO might be the consequence of a too-low ECMO blood flow, we constructed a scatterplot to assess the blood flow used in survivors and non-survivors. These showed no differences between survivors and non-survivors (Appendix Fig. 4 in Online Supplement).

Mediation analyses {#Sec16}
------------------

The results of the mediation analyses are shown in the Online Supplement Figs. 5, 6, 7, 8, 9 and 10. In the models with ΔP as the independent variable, its effect on mortality was not mediated by the PEEP level (Appendix Fig. 5 in the Online Supplement), the Pplat level (Appendix Fig. 6 in the Online Supplement) or compliance (Appendix Fig. 7 in the Online Supplement). In the models with ΔP as the mediator, the impact of the PEEP level (Appendix Fig. 8 in the Online Supplement), the Pplateau level (model 5, Appendix Fig. 9 in the Online Supplement) and compliance (model 6, Appendix Fig. 10 in the Online Supplement) was fully mediated by ΔP.

Discussion {#Sec17}
==========

With ECMO, it is possible to 'rest' the lungs by using lower tidal volumes, lower airway pressures, and lower FiO~2~, thereby decreasing the iatrogenic consequences of mechanical ventilation \[[@CR8]\]. There are several systematic reviews and metaanalysis of mechanical ventilation settings in patients under ECMO \[[@CR10], [@CR30]--[@CR33]\]. The present study analyzing the largest cohort of ARDS patients under ECMO for refractory hypoxemia allowed the assessing of the associations between ventilatory settings and parameters and outcome. The results of this analysis using individual patient data suggest that the ΔP is the ventilatory parameter that best stratifies risk of death in ARDS patients receiving ECMO for refractory hypoxemia.

We grouped patients from several centers across the world, increasing the external validity of the study. Ventilatory parameters influencing mortality were identified; these may prove helpful for physicians to improve ventilator settings in patients under ECMO. A strong point of the present study is the use of multiple imputation of missing values, a technique that is designed to increase the power of the analysis and produce models that are more statistically reliable and applicable within clinical practice.

The main finding that a higher ΔP during ECMO is associated with worse survival is consistent with studies in patients with ARDS, both those conventionally treated \[[@CR7], [@CR18], [@CR19]\] and those receiving ECMO \[[@CR9], [@CR29]\]. The results of the present analysis builds upon the results of several preclinical studies in animals showing that cell and tissue damage is more closely related to the amplitude of cyclic stretch than to maximal or sustained stretch, suggesting a causal link between driving pressure and lung injury \[[@CR34], [@CR35]\]. A decline in ΔP after ECMO initiation was established largely by tidal volume and plateau pressure changes, as there were only small changes in PEEP settings.

The benefit of higher PEEP levels in ARDS remains controversial \[[@CR5]\]. The Extracorporeal Life Support Organization (ELSO) guideline recommends a PEEP of 10 cmH~2~O during ECMO \[[@CR21]\]. A recent study also suggests that higher levels of PEEP during ECMO for patients with ARDS are associated with reduced mortality \[[@CR9]\]. In the present analysis, however, higher PEEP was not associated with better outcome when included in the multivariable analysis. Recent evidence suggests that the change in ΔP resulting from an increase in PEEP levels is an important predictor of survival in patients with ARDS \[[@CR7]\]. In other words, changes in the PEEP level could improve outcome through its effects on the ΔP: if the ΔP decreases, outcomes could improve, but when ΔP increases, outcomes could become worse.

Opposite to our findings, use of higher FiO~2~ during ECMO has been found to be independently associated with a worse outcome in other studies. While it could be that the need for higher FiO~2~ simply reflects disease severity, it could mean that: (1) too high FiO~2~ are harmful; or (2) there was insufficient oxygenation from ECMO device, because of an insufficiently low blood flow with respect to cardiac output in some patients. Indeed, high FiO~2~ may induce pulmonary injury, at least in part by increased oxidative stress via increased levels of reactive oxygen-derived free radicals, with an influx of inflammatory cells, increased permeability and endothelial cell injury \[[@CR36], [@CR37]\].

An important relationship between duration of ventilation prior to ECMO initiation and mortality has previously been reported \[[@CR38], [@CR39]\]. This was not confirmed in the present study and in another large cohort analyzing mechanical ventilation during ECMO \[[@CR9]\]. One possible explanation is that in this cohort almost all patients received ECMO within 7 days after the start of mechanical ventilation. Also, the risk of death calculated by prognostic scores was not retained in our multivariable analysis. One possible explanation for this is that severity scores are usually calculated from data collected at ICU admission and the first day of stay in the ICU, and not at ECMO initiation. The finding that higher lactate was associated with mortality in the present cohort is similar to several reports in patients receiving ECMO for respiratory failure \[[@CR20], [@CR39]\] and cardiogenic shock \[[@CR40]\].

Tidal volume size, PEEP and Pplat levels in patients before ECMO in the present study were similar to those previously reported \[[@CR29]\]. In a recent study, higher Pplat levels were found as the only ventilatory parameter associated with mortality (of note, ΔP was not included in the model used in that study) \[[@CR29]\]. The Predicting Death for Severe ARDS on VV-ECMO (PRESERVE) score reported Pplat levels before ECMO as one important prognostic factor for long-term mortality \[[@CR20]\]. Finally, the Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score included Ppeak levels before ECMO in its model to assess short-term mortality \[[@CR41]\].

From a physical perspective, the process of lung injury must be related to the energy transfer from the ventilator to the lung. At each breath, the ventilator transfers some energy to the respiratory system, and there is considerable dissipation of energy, probably resulting in heat and lung tissue damage during each breath. This energy is closely related to the ΔP and respiratory rate \[[@CR42]\]. ECMO could allow the lung to rest, through the reduction of driving pressure via tidal volume and plateau pressure reduction and/or increase of PEEP, and through the decrease in respiratory rate via increase in sweep gas flow and PaCO~2~ removal.

Mechanical ventilators are set using diverse combinations of tidal volume sizes, airway pressures, air flows, and respiratory rates. These variables, together, could be quantified as mechanical power \[[@CR43]\]. Recently, it was shown that lung injury is highly dependent from mechanical power, that is, the product of tidal volume size, Pplat, and respiratory rate \[[@CR43]\]. If mechanical power is 'excessive', then the chemical bonds of the polymers composing the extracellular matrix could get disrupted \[[@CR43]\]. The relationship between mechanical power and outcomes in patients undergoing ECMO needs further attention in future studies.

The present analysis has several limitations, including its non-randomized design, which precludes any inference of causality regarding the association between ΔP and outcome. In addition, it cannot be excluded that residual confounding not accounted for in this study might have biased the results. Also, ventilatory settings and parameters were collected only once per day in the original studies. Mechanical ventilation, however, is a continuous and dynamic intervention, and settings may have changed rapidly with a 24-h period, especially shortly after the start of ECMO. Data from only the first 3 days of ECMO were included in the analysis of mortality because recent studies have suggested that ventilation during such a period is the most important factor related to the prognosis of patients \[[@CR9], [@CR33]\]. Whether specific ventilatory strategies after day 3 would change patient outcomes is yet to be determined, and larger prospective studies may shed light onto this aspect. Also, the fact that ΔP could represent only a marker of disease severity should be taken in account. It was impossible to determine the number of patients with severe sepsis or septic shock, and the potential impact of this condition in the outcome was not assessed. However, since most of the patients presented with pneumonia and use of vasoactive drugs, one could assume that most of them had severe sepsis and septic shock. The heterogeneity of the different study populations, with diverse indications of ECMO and dissimilar approaches to ECMO and ventilatory management, may further limit the inferences that can be drawn from the present analysis. While grouping patients from several centers around the world may improve the study's generalizability, the fact that most studies were conducted in expert centers may also serve to limit generalizability outside of these settings. Prone position has clearly been shown to benefit patients with severe ARDS \[[@CR44]\], and proning could have affected the results of this analysis. Information on proning was unfortunately largely lacking in the databases. However, proning of patients receiving extracorporeal blood treatment was, at least until recently, model hardly performed. Finally, the impact of ventilatory parameters in the subgroup of patients with intracranial hemorrhage or severe bleeding events was not specifically addressed in the present study.

In conclusion, the results from this analysis suggest that a low ΔP during ECMO is independently associated with improved in-hospital survival in patients with ARDS treated with ECMO. Randomized controlled trials should test if strategies aiming at low ΔP during ECMO are safe, feasible and effective in improving outcome of ARDS patients with refractory hypoxemia.
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The ReVA Research Network and the PROVE Network Investigators are listed in full in ESM 2.

**Take-home message:** "Maintenance of a low driving pressure during the first days of ECMO in patients with acute respiratory distress syndrome is associated with reduced mortality".
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